



Proteomics International

LABORATORIES LTD

ASX/Media Release

29 January 2018

ASX code: PIQ

Diabetic kidney disease patent granted in Japan

Medical technology company Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ), a leader in predictive diagnostics and analytical services, has been granted a patent in Japan for the company's world leading diagnostic and prognostic test for diabetic kidney disease, "PromarkerD".

- **Japan's annual healthcare expenditure on diabetes is the 5th highest in the world at USD28 billion**
- **Early detection of diabetic kidney disease is particularly important in Japan because organ transplants are rare**
- **PromarkerD patent portfolio now covers Japan, Australia, China, Russia, Singapore, and USA, with other major jurisdictions pending**
- **Industry experts leading Proteomics International's commercialisation strategy in Japan**
- **Discussions ongoing with potential licensing partners for PromarkerD in the USA, Mexico, Japan, Australia, China and Europe**

Japan is home to 7.2 million adults with diabetes, according to the International Diabetes Federation, and the country spends USD28 billion a year on diabetes-related healthcare. The nation's healthcare expenditure on diabetes is the fifth highest in the world, behind the United States, China, Germany and India.

Early detection and treatment of diabetic kidney disease is particularly important in Japan, where cultural, legal and religious concerns have seen the country shy away from organ transplantation. According to the Tokyo-based Japan Organ Transplant Network, only 380 transplants were conducted in Japan last year.

Proteomics International received confirmation last week that Japanese Patent number 2017-136403, titled "Biomarkers Associated with Pre-Diabetes, Diabetes and Diabetes Related Conditions" was granted on the 21 December 2017 and will extend until 20 September 2031.

Japan is a key market for Proteomics International and Director Mr Roger Moore (former President of Novo Nordisk, Japan) and business development advisor Dr Masafumi Yoshimoto [ASX: 22 Nov 17] are coordinating commercialisation discussions in the country.

Patent protection for the PromarkerD test has already been granted in Australia, China, Russia, Singapore, and USA, and with the addition of Japan covers a potential market size of 161 million adult diabetics. Patents are pending in Brazil, Canada, Indonesia, India, and Europe, which if granted will cover an additional 156 million diabetics. In total this represents 317 million of the world's estimated 425 million diabetic population.

PromarkerD - a predictive and diagnostic test for diabetic kidney disease (www.PromarkerD.com)

PromarkerD is a breakthrough blood test that uses a protein 'fingerprint' to measure kidney disease

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

in patients with diabetes. This ground-breaking test can both diagnose and predict disease.

In results presented to the American Diabetes Association's 77th Annual Scientific Sessions [ASX: 10 June 17] and published in the prestigious journal *Diabetes Care* [ASX: 6 September 17], PromarkerD can correctly predict 86% of the previously kidney disease-free diabetic patients who go on to develop chronic kidney disease. PromarkerD can also diagnose diabetic patients already suffering from chronic kidney disease that the current standard tests miss. There is currently no available test for predicting the onset of diabetic kidney disease.

The official launch of PromarkerD will be in Central America in March as part of Proteomics International's stepped approach to commercialise the test in global markets using a range of platforms. This has involved the manufacture of a new kit version of PromarkerD to produce an in vitro diagnostic (IVD) immunoassay that could be used in clinical laboratories, and the existing, validated Laboratory Developed Test (LDT) version which uses mass spectrometry for specialised certified laboratories.

Proteomics International is engaged with a number of potential partners to bring PromarkerD to market as a clinical diagnostic test (IVD or LDT) or companion diagnostic (CDx) in multiple jurisdictions.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. Proteomics International is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.